Immunogenicity
Three participants (14.3%) developed anti-caplacizumab antibodies during treatment. Neither pre-existing antibodies nor anti-drug antibodies were found to have an influence on the time to platelet count response, plasma caplacizumab concentrations, VWF:RCo, or VWF:Ag levels.